<DOC>
	<DOCNO>NCT01317186</DOCNO>
	<brief_summary>In chronic kidney disease calcium ( Ca ) phosphate ( P ) metabolism disorder common also one lead cause morbidity population . FGF23 novel factor contribute Ca-P disorder . It hypothesize FGF 23 increase mediate asymmetric dimethylarginine ( ADMA ) . The aim study evaluate hypothesis .</brief_summary>
	<brief_title>The Role FGF23 Asymmetric Dimethylarginine ( ADMA ) Chronic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>N , N-dimethylarginine</mesh_term>
	<criteria>age 18 65 year old chronic kidney disease stage 24 presence diabetes mellitus ischemic hearth disease take vitamin therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>FGF 23</keyword>
	<keyword>ADMA</keyword>
	<keyword>chronic kidney disease</keyword>
	<keyword>Ca-P metabolism disorder</keyword>
</DOC>